

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

**Sensei Biotherapeutics, Inc.**

---

(Name of Issuer)

**Common Shares, no par value per share**

---

(Title of Class of Securities)

**81728A207**

---

(CUSIP Number)

**02/18/2026**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

---

SCHEDULE 13G

**CUSIP No.** 81728A207

Names of Reporting Persons

1

Trails Edge Capital Partners, LP

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares 5 Sole Voting Power

Beneficially 126,010.00  
Owned by Shared Voting Power  
Each 6  
Reporting 0.00  
Person  
With: Sole Dispositive Power  
7  
126,010.00  
Shared Dispositive  
8 Power  
0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9 126,010.00  
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10   
Percent of class represented by amount in row (9)

11 9.9 %

12 Type of Reporting Person (See Instructions)  
IA, PN

**Comment for Type of Reporting Person:** See Item 4 for additional information.

## SCHEDULE 13G

**CUSIP No.** 81728A207

Names of Reporting Persons

1 Trails Edge Biotechnology Master Fund, LP  
Check the appropriate box if a member of a Group (see instructions)

2  (a)  
 (b)

3 Sec Use Only  
Citizenship or Place of Organization

4 CAYMAN ISLANDS  
Sole Voting Power

5 126,010.00  
Number of Shares Beneficially Owned by Each Reporting Person With: Shared Voting Power  
6 0.00  
Sole Dispositive Power  
7 126,010.00  
Shared Dispositive  
8 Power  
0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9 126,010.00  
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

11 Percent of class represented by amount in row (9)

9.9 %

Type of Reporting Person (See Instructions)

12

PN

**Comment for Type of Reporting Person:** See Item 4 for additional information.

## SCHEDULE 13G

**CUSIP No.** 81728A207

Names of Reporting Persons

1

Ortav Yehudai

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

126,010.00

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person  
With:

Shared Voting Power

6

0.00

Sole Dispositive Power

7

126,010.00

Shared Dispositive

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

126,010.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

9.9 %

Type of Reporting Person (See Instructions)

12

IN

**Comment for Type of Reporting Person:** See Item 4 for additional information.

## SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Sensei Biotherapeutics, Inc.

(b) Address of issuer's principal executive offices:

1405 Research Blvd, Suite 125, Rockville, MD 20850

Item 2.

Name of person filing:

(a) This report on Schedule 13G is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"), Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology"), and Ortav Yehudai ("Mr. Yehudai"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers".

Address or principal business office or, if none, residence:

(b)

The address for each Filer is 3455 Peachtree Road NE, 5th Floor, Atlanta, GA 30326.

Citizenship:

(c)

See Item 4 of the cover page of each Filer.

Title of class of securities:

(d)

Common Shares, no par value per share

CUSIP No.:

(e)

81728A207

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k)  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a) As of February 18, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate of 126,010 shares (the "Shares") of Common Stock, no par value per share (the "Common Stock"), of Sensei Biotherapeutics, Inc. (the "Issuer"). The 126,010 Shares reported as beneficially owned on this Schedule 13G by each Filer consists of (i) 125,000 Shares held directly by Trails Edge Biotechnology, and (ii) 1,010 Shares underlying 1.01 share of Series B Convertible Stock (the "Series B Preferred Shares") held directly by Trails Edge Biotechnology. The securities beneficially owned by each Filer excludes 360,000 Shares underlying 360 Series B Preferred Shares which contain an issuance limitation that prohibits the holder from converting the Series B Preferred Shares to the extent that after giving effect to such issuance after the conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the other Filers) would beneficially own in excess of 9.99% of the Shares outstanding immediately after giving effect to the issuance of the Shares issuable upon conversion of the Series B Preferred Shares. As a result, Trails Edge Biotechnology beneficially owns 9.9% of the outstanding Shares of the Issuer as of the Event Date. Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own 9.9% of the outstanding Shares of the Issuer as of the Event Date. Ownership percentages are based on 1,261,290 shares of Common Stock issued and outstanding as of November 10, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 14, 2025.

(b)

Percent of class:

9.9% %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

126,010.00

(ii) Shared power to vote or to direct the vote:

0.00

(iii) Sole power to dispose or to direct the disposition of:

126,010.00

(iv) Shared power to dispose or to direct the disposition of:

0.00

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Trails Edge Capital Partners, LP

Signature: /s/ Trails Edge Capital Partners, LLC, GP of  
Trails Edge Capital Partners, LP /s/ Ortav Yehudai  
Name/Title: Ortav Yehudai / Chief Investment Officer of  
Trails Edge Capital Partners, LLC  
Date: 02/25/2026

Trails Edge Biotechnology Master Fund, LP

Signature: /s/ Trails Edge GP, LLC, GP of Trails Edge  
Biotechnology Fund GP, LP, GP of Trails Edge  
Biotechnology Master Fund, LP /s/ Ortav Yehudai  
Name/Title: Ortav Yehudai / Chief Investment Officer of  
Trails Edge GP, LLC  
Date: 02/25/2026

Ortav Yehudai

Signature: /s/ Ortav Yehudai  
Name/Title: Ortav Yehudai / Individual  
Date: 02/25/2026

## **Exhibit Information**

Exhibit 1- Joint Filing Agreement

**JOINT FILING AGREEMENT**

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate.

Dated: February 25, 2026

**Trails Edge Capital Partners, LP**

By: Trails Edge Capital Partners, LLC, the general partner of Trails Edge Capital Partners, LP

By:  /s/ Ortav Yehudai  
Name: Ortav Yehudai  
Title: Chief Investment Officer

**Trails Edge Biotechnology Master Fund, LP**

By: Trails Edge GP, LLC, the general partner of Trails Edge Biotechnology Fund GP, LP, the general partner of Trails Edge Biotechnology Master Fund, LP

By:  /s/ Ortav Yehudai  
Name: Ortav Yehudai  
Title: Chief Investment Officer

**Ortav Yehudai**

/s/ Ortav Yehudai

---